吉西他滨联合替吉奥治疗晚期胆囊癌的疗效

Curative Effect of Gemcitabine Combined with S-1 on Advanced Gallbladder Cancer

目的探讨吉西他滨联合替吉奥治疗晚期胆囊癌的临床疗效。方法将80例晚期胆囊癌患者按治疗方法的不同分为对照组(n=38)和观察组(n=42例)。2组均在化疗前常规预防性应用5-羟色胺3(5-HT3)受体拮抗剂止吐治疗,同时给予替吉奥胶囊治疗。在此基础上,观察组给予注射用盐酸吉西他滨治疗。观察2组治疗前、治疗2个周期后血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、神经元特异性烯醇化酶(NSE)]水平及临床疗效。结果观察组总有效率为64.29%,高于对照组的28.95%(P<0.05)。2组治疗前血清CEA、CA125、CA19-9、NSE水平比较差异无统计学意义(P>0.05),观察组治疗2个周期后血清CEA、CA125、CA19-9、NSE水平均低于对照组(均P<0.05)。结论与替吉奥单药治疗相比,吉西他滨联合替吉奥治疗晚期胆囊癌的疗效更好。

Objective To explore the curative effect of gemcitabine combined with S-1 on advanced gallbladder cancer.Methods Eighty patients with advanced gallbladder cancer were divided into control group(n=38)and observation group(n=42).Both groups were treated with prophylactic serotonin 3(5-HT3)receptor antagonist and S-1 capsules.Additionally,the observation group was given gemcitabine hydrochloride.Serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 19-9(CA19-9)and neuron-specific enolase(NSE)levels and clinical curative effect were observed after 2 cycles of treatment.Results The total effective rate in observation group(64.29%)was higher than that in control group(28.95%)(P<0.05).There were no significant differences in serum CEA,CA125,CA19-9 and NSE levels between the two groups before treatment(P>0.05).After treatment,the levels of CEA,CA125,CA19-9 and NSE in observation group were lower than those in control group(P<0.05).Conclusion The combination of gemcitabine and S-1 is superior to S-1 alone for treating advanced gallbladder cancer.